Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H6F2
UPID:
TM38A_HUMAN
Alternative names:
Transmembrane protein 38A
Alternative UPACC:
Q9H6F2; A8K9P9
Background:
The Trimeric intracellular cation channel type A, also known as Transmembrane protein 38A, plays a crucial role in cellular function by acting as a monovalent cation channel. It is essential for the rapid release of intracellular calcium and may serve as a potassium counter-ion channel, ensuring the synchronization of calcium release from intracellular stores.
Therapeutic significance:
Understanding the role of Trimeric intracellular cation channel type A could open doors to potential therapeutic strategies.